NASDAQ:BIOC Biocept - BIOC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.35 0.00 (0.00%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.33▼$0.3750-Day Range$0.24▼$0.6052-Week Range$0.24▼$2.43Volume50,456 shsAverage Volume163,871 shsMarket Capitalization$6.01 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biocept MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,034.8% Upside$4.00 Price TargetShort InterestHealthy0.81% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 stars 3.0 Analyst's Opinion Consensus RatingBiocept has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Biocept has a forecasted upside of 1,034.8% from its current price of $0.35.Amount of Analyst CoverageBiocept has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.81% of the outstanding shares of Biocept have been sold short.Short Interest Ratio / Days to CoverBiocept has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biocept has recently increased by 35.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiocept does not currently pay a dividend.Dividend GrowthBiocept does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOC. Previous Next 2.1 News and Social Media Coverage News SentimentBiocept has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biocept this week, compared to 1 article on an average week.Search Interest4 people have searched for BIOC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Biocept to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biocept insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.92% of the stock of Biocept is held by insiders.Percentage Held by InstitutionsOnly 10.04% of the stock of Biocept is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Biocept is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biocept is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiocept has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biocept (NASDAQ:BIOC) StockBiocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.Read More Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOC Stock News HeadlinesMarch 29, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Now Covered by Analysts at StockNews.comMarch 28, 2023 | americanbankingnews.comBiocept (BIOC) to Release Quarterly Earnings on WednesdayMarch 30, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 24, 2023 | finance.yahoo.comEnrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal MetastasesMarch 22, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Research Coverage Started at StockNews.comMarch 20, 2023 | marketwatch.comCirculating Tumor DNA (ctDNA) Market Key Vendors and Forecast till 2028February 27, 2023 | marketwatch.comWith Astonishing CAGR, Cell-Free DNA (cfDNA) Testing Market Generate Revenue at Significant Rate, 2028February 13, 2023 | marketwatch.comCirculating Tumor Cells (CTCs) Detectors Market Increasing Demand with Leading Competitors, Comprehensive Analysis, Forecast 2028March 30, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 13, 2023 | marketwatch.comCirculating Tumor Cells Market 2023 Business Scenario | Top Factors that Will Boost the Circulating Tumor Cells MarketFebruary 13, 2023 | finance.yahoo.comBiocept, Inc. (BIOC) Stock Historical Prices & Data - Yahoo FinanceJanuary 31, 2023 | marketwatch.comCirculating Tumor Cells Market Share 2023 Research by Growth Developments, Emerging Demand, Future Trends and Business Statistics Forecast to 2028January 6, 2023 | finance.yahoo.comBiocept to Explore Strategic Alternatives and Implement Restructuring PlanDecember 31, 2022 | thestreet.comBiocept (BIOC) Stock Soaring After Expanding Blood-Based Test MenuDecember 25, 2022 | finance.yahoo.comBiocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call TranscriptNovember 21, 2022 | finance.yahoo.comBiocept Reports Third Quarter 2022 Financial ResultsNovember 18, 2022 | finance.yahoo.comBiocept Appoints Financial Executive Quyen Dao-Haddock to its Board of DirectorsNovember 16, 2022 | finance.yahoo.comBiocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous SystemNovember 10, 2022 | finance.yahoo.comBiocept Reports Second Quarter 2022 Financial ResultsNovember 8, 2022 | marketwatch.comCell Free DNA Kit Market Trends, Business Overview, Industry Growth, and Forecast 2022 To 2028October 20, 2022 | streetinsider.comForm 8-K BIOCEPT INC For: Oct 18 - StreetInsider.comOctober 19, 2022 | finance.yahoo.comBiocept to Present at the LD Micro Main Event XVOctober 17, 2022 | businesswire.comBiocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System - Business WireOctober 17, 2022 | finance.yahoo.comBiocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System - Yahoo FinanceOctober 17, 2022 | finance.yahoo.comBiocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous SystemOctober 16, 2022 | businesswire.comBiocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System - Business WireOctober 14, 2022 | proactiveinvestors.comNews snapshot: Mandalay Resources, Algernon Pharmaceuticals, The Valens Company, Todos Medical... - Proactive Investors USASee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOC Company Calendar Last Earnings11/15/2021Today3/30/2023Next Earnings (Estimated)4/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees104Year Founded1993Price Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+1,108.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,820,000.00 Net Margins-32.99% Pretax Margin-32.74% Return on Equity-49.18% Return on Assets-28.56% Debt Debt-to-Equity Ratio0.04 Current Ratio5.13 Quick Ratio4.86 Sales & Book Value Annual Sales$61.25 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.15Miscellaneous Outstanding Shares17,060,000Free Float16,902,000Market Cap$5.65 million OptionableOptionable Beta1.01 Social Links Key ExecutivesSamuel D. RiccitelliChairman, President & Chief Executive OfficerPhilippe MarchandChief Operating OfficerAntonino MoralesChief Financial Officer, Secretary & DirectorNathaniel SweedMedical DirectorDarrell TaylorSVP, Chief Legal & Compliance OfficerKey CompetitorsAnPac Bio-Medical ScienceNASDAQ:ANPCAclarionNASDAQ:ACONOpGenNASDAQ:OPGNVyant BioNASDAQ:VYNTCentogeneNASDAQ:CNTGView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 15,800 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions BIOC Stock - Frequently Asked Questions Should I buy or sell Biocept stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares. View BIOC analyst ratings or view top-rated stocks. What is Biocept's stock price forecast for 2023? 1 brokerages have issued 12-month price objectives for Biocept's stock. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,108.8% from the stock's current price. View analysts price targets for BIOC or view top-rated stocks among Wall Street analysts. How have BIOC shares performed in 2023? Biocept's stock was trading at $0.53 on January 1st, 2023. Since then, BIOC stock has decreased by 37.6% and is now trading at $0.3309. View the best growth stocks for 2023 here. Are investors shorting Biocept? Biocept saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 139,000 shares, an increase of 35.9% from the February 28th total of 102,300 shares. Based on an average daily trading volume, of 164,500 shares, the short-interest ratio is currently 0.8 days. View Biocept's Short Interest. When is Biocept's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 5th 2023. View our BIOC earnings forecast. How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) released its earnings results on Monday, November, 15th. The medical research company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million. Biocept had a negative net margin of 32.99% and a negative trailing twelve-month return on equity of 49.18%. During the same period in the prior year, the firm posted ($0.43) EPS. When did Biocept's stock split? Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Michael Nall's approval rating as Biocept's CEO? 4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST). What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." Who are Biocept's major shareholders? Biocept's stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David F Hale and David F Hale. View institutional ownership trends. How do I buy shares of Biocept? Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $0.33. How much money does Biocept make? Biocept (NASDAQ:BIOC) has a market capitalization of $5.65 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. How many employees does Biocept have? The company employs 104 workers across the globe. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225. This page (NASDAQ:BIOC) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.